The clinical trials that established semaglutide's efficacy — particularly STEP-1 through STEP-4 — enrolled patients of both sexes, but the sex-specific analysis reveals important differences that have implications for how GLP-1 protocols should be individualized for women.
Hormonal Interactions
Estrogen modulates GLP-1 receptor expression and signaling throughout the body. Higher estrogen levels are associated with greater GLP-1 receptor sensitivity — which means that the hormonal fluctuations of perimenopause and menopause directly affect how women respond to GLP-1 agonist therapy. Post-menopausal women with low estrogen may require different dosing approaches than premenopausal women, and HRT in peri/postmenopausal women on semaglutide may enhance GLP-1 efficacy.
Side Effect Profile Differences
Women experience higher rates of nausea, vomiting, and gastrointestinal side effects on GLP-1 agonists compared to men — an observation consistent across multiple trials and post-market data. This appears to relate to differences in gastric motility, gut hormone levels, and GLP-1 receptor expression in GI tissue. Starting at lower doses and titrating more slowly reduces these effects without significantly compromising efficacy.
Muscle Preservation Is Critical
Women lose proportionally more lean mass than men on GLP-1 therapy, likely due to baseline differences in muscle mass and the anabolic effects of testosterone. Protein targets of 1.6–2.2g/kg of ideal body weight, resistance training 3x weekly, and consideration of testosterone optimization are all essential components of a women's GLP-1 protocol designed to preserve muscle while losing fat.
Menstrual Cycle Effects
Significant weight loss can affect menstrual cycle regularity — both through direct effects on hypothalamic-pituitary-gonadal axis signaling and through changes in adipose tissue (which produces estrogen peripherally). Women of reproductive age on GLP-1 therapy should be monitored for cycle changes and understand that contraceptive efficacy may be affected in the early titration phase when GI effects are most pronounced.